230 Users Online
Hemarthrosis Treatment Market Segmented By Treatment Type such as Surgical hemarthrosis treatment in Synovectomy, Joint Replacement and Drugs
Hemophilia is a genetic disorder which is caused when factor IX or VIII also known as the clotting protein is either missing or defective. Hemophilia involves a common complication of joint bleeding. Excess bleeding of the joints result into a permanent damage to the patient’s joint, which sometimes could also lead to permanent disability.
The frequency and severity of the joint bleeding determines how likely a patient is to develop permanent disability. This condition caused by joint bleeding leading to the swelling of the joints, deformity, and severe pain is referred to as hemarthrosis, as the symptoms are quite similar to arthritis symptoms but also, involves blood.
The bleeding in the joint immensely affects the surrounding cartilage of the bone. Hemarthrosis treatment entirely depends on the underlying cause of the joint bleeding and also, on the severity of the damage of the joint. Different surgeries and therapies are available for hemarthrosis treatment and several researches are ongoing, globally.
Hemophilia take factor replacement therapy is one hemarthrosis treatment option that is widely used for hemarthrosis treatment. This replacement therapy involves a medication for the replacement of the missing or defective clotting protein, which prevents hemarthrosis from happening in the first place.
Increasing incidence of hemarthrosis because of high incidence of hemophilia across regions is expected high demand for hemarthrosis treatment throughout the forecast period.
Several factors, such as, increasing number of trauma cases by any injury or sprain, increased use of anticoagulants, high incidence of inflammation of the joints, and increasing incidence of arthritis and leukemia are also some of the primary factors that might contribute to the market growth of hemarthrosis treatment market during the forecast period. Increase in government funding and support for ongoing research and development related to hemarthrosis treatment might also boost market growth for hemarthrosis treatment across regions during the forecast period.
However, high costs associated with replacement therapies and surgeries for hemarthrosis treatment and less affordability for hemarthrosis treatment in the developing regions could obstruct market growth for hemarthrosis treatment market during the forecast period.
|On the basis of Treatment Type||
|On the basis of End Use||
Growth of the hemarthrosis treatment market is highly attributed to the high incidence of hemophilia cases and trauma injuries cases in the North America region. Consistently increasing awareness on the wide hemarthrosis treatment option available and increase in healthcare expenditure is also expected to drive market growth for hemarthrosis treatment in the region throughout the forecast period.
Europe’s market for hemarthrosis treatment is expected to witness a robust market growth owing it to the improved healthcare infrastructure in the region and increase in government support for research and development of hemarthrosis treatment.
Middle East & Africa’s hemarthrosis treatment market and Latin America’s market for hemarthrosis treatment is expected to grow at a decent rate owing it to less awareness on hemophilia and hemarthrosis treatment.
Some of the market participants in the Global Hemarthrosis Treatment market identified across the value chain include: Novartis AG, Pfizer Inc., Sun Pharmaceuticals Ltd, Merck KGaA, Bayer Healthcare, BioMarin Pharmaceutical, Inc., Biogen, Chugai Pharmaceutical Co., Novo Nordisk, and Shire Plc.